Does timing of blood pressure med matter for kidney protection? new trial investigates
NCT ID NCT07259512
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 trial tests whether taking ramipril once daily or split into two smaller doses works better for protecting kidney function in 80 adults with chronic kidney disease and heart failure. Over 30 days, researchers will measure changes in blood markers of kidney function, inflammation, and oxidative stress. The goal is to find the best dosing schedule to slow kidney decline in this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ramipril (an ACE inhibitor)
What this could lead to
If successful, this study could show that splitting the ramipril dose improves kidney protection in patients with both chronic kidney disease and heart failure.
What could go wrong
This is a small, short-term trial (80 patients, 30 days) looking at biomarkers, not long-term outcomes. Results may not translate to better kidney or heart health over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UNS Hospital
RECRUITINGKartasura, Central Java, Indonesia
Contact Phone: •••-•••-•••• Email: •••••@•••••